Afeletecan

Drug Profile

Afeletecan

Alternative Names: BAY 38-3441

Latest Information Update: 22 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Camptothecins; Dipeptides; Glycoconjugates
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 26 Nov 2002 Results from two phase I studies have been added to the adverse events and Cancer therapeutic trials sections
  • 25 Nov 2002 A study has been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
  • 10 Dec 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top